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Abstract
Objective: To identify the roles of CXCL12 and CXCR4 and the associated mechanism involved
in perineural invasion of prostate cancer.
Methods: The distribution and expression of CXCL12, CXCR4, MMP-2 and MMP-9 in human
prostate cancer and in tumor cells invading nerve tissue were studied with immunohistochemical
staining. The effects of exogenous CXCL12 and CXCR4 antagonist AMD3100 on PC3 prostate
cancer cells invasiveness were assessed in vitro and in vivo.
Results: The expression of CXCL12, CXCR4, MMP-2, and MMP-9 in human prostate cancer were
higher than those in hyperplastic prostate tissues (P < 0.05). In vitro CXCL12 could stimulate the
PC3 cells invasiveness (P < 0.05) while AMD3100 could inhibit invasiveness. In vivo, the number of
nerves around the tumor tissue in the group treated with CXCL12 was significantly higher than
that found in the control group (P < 0.05). Both the control group and the CXCL12-treated group
had more nerves number near the tumor tissue than it found in the AMD3100-treated group. The
positive cell number of CXCL12, CXCR4, MMP-2, MMP-9, and NGF expression ranked from
highest to lowest, were the CXCL12-treated, the control, and the AMD3100-treated group(P <
0.05).
Conclusion: CXCL12 and its receptor CXCR4 along with MMP-2 and MMP-9 are related with
prostate cancer perineural invasion.
Introduction
Perineural invasion (PNI) of malignant tumor cells means
tumor cells tend to encroach upon nerve fibers and invade
the lamellar sheath, leading to infiltration and metastasis.
This phenomenon is often seen in adenoid cystic carci-
noma, pancreatic cancer and prostate cancer [1]. Prostate
cancer PNI usually localizes in a few important nerves,
influencing the patients' quality of life and making it dif-
ficult to remedy. Residual tumor cells in nerve tissue may
contribute to local recurrence and metastasis and influ-
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mechanism of PNI involves the microenvironment
around the nerve tract that is suitable for tumor cell
growth and proliferation. This situation promotes tumor
cell infiltration and diffusion along nerve fibers [3].
Chemokines are small, secreted peptides that control
adhesion and transendothelial migration of leukocytes,
lymphocytes, and monocytes, especially during immune
and inflammatory reactions. Chemokines combine with
G-protein-coupled-receptors to perform their function.
Chemokines and their receptors have significant roles in
tumor metastasis, recurrence and angiogenesis [4].
Among the family of chemokines and their receptors that
significantly contribute to the initiation and development
of tumors, CXCL12 and its receptor CXCR4 are the most
frequently mentioned. CXCR4 is the unique receptor for
CXCL12, also named stromal cell-derived factor 1 (SDF1).
Prostate cancer cells secrete many chemokines and their
receptors, also found in cells in other tissues of the body,
and these chemokines are involved in the prostate cancer
cells' organ-specific metastasis [5]. During the process of
prostate cancer PNI, MMP-2 and MMP-9 play an impor-
tant role in degrading the matrix around the tumor and
the nerve tissue. Our research aims to study CXCL12,
CXCR4, MMP-2 and MMP-9 expression in prostate cancer
PNI using in vitro experiments, animal model experi-
ments and human prostate cancer tissue. The study was
the first time to report the roles of CXCL12 and CXCR4 in
PNI of prostate cancer.
Materials and methods
Cell lines and materials
Human androgen-independent prostate cancer cell line
PC3 was provided by the central experiment lab of Tianjin
Cancer Hospital.
Transwell experiment
PC3 cells were cultured in RPMI 1640 without serum at
37°C with 5% CO2 and were adjusted to 1 × 105-1 × 106
cells/ml. The liquid extracellular matrix (ECM) gel
(Sigma-Aldrich, St. Louis, USA) was pre-cooled to 2–8°C
and 16.5μl was added to the upper surface of each Tran-
swell chamber filter (Corning corporation, New York,
USA). The chambers were incubated at 37°C with 5%
CO2 for one hour to allow the matrix to solidify and then
1 × 104-1 × 105 PC3 cells in suspension were added to the
upper chambers. For the controls, 600 μl serum-free
medium was added to the lower chamber. For the
CXCL12 experimental wells, 600 μl serum-free medium
supplemented with 0.1 μg CXCL12 (Jingmei corporation,
Tianjin, China, reconstituted with Saline) was added to
the lower chamber. For the CXCR4 antagonist experimen-
tal wells, 600 μl serum-free media supplemented with 12
pmol AMD3100 (Sigma corporation, USA, reconstituted
with Saline) was added to the lower chamber. The cham-
bers were incubated for 20 hours at 37°C with 5% CO2.
The upper surface of the filter was removed using a cotton
swab. Cells that invaded through the ECM and the filter to
the lower surface were fixed using 5% glutaraldehyde and
were then stained with H&E. The cell number in five fields
(up, down, median, left, right. ×400) were counted for
each chamber, and the average was determined. Each
experimental condition was repeated four times.
Model of prostate cancer and tumor experiments in BALB/
C nude mice
BALB/C nude mice were obtained from the Academy of
Military Medical Sciences of China. Six to eight-week-old,
20 to 25 g BALB/C nude mice (14 males and 14 females)
were used to establish the perineural invasion model.
Each mouse received a groin injection of 1 × 106 PC3 cells.
On the 18th day after inoculation, the mice were divided
randomly into three groups and received treatment for 10
days. In the CXCL12 group (n = 8) each mouse was treated
with CXCL12 at 0.1 μg/day[6]. In the AMD3100 group (n
= 10) each mouse was treated with 10 pmol/day
AMD3100[7]. In the control group (n = 10) each mouse
was treated with 0.1 ml/day sodium chloride. The mice
were sacrificed after 10 days of treatment, and the tumor
mass and surrounding tissue were removed, fixed with
formalin and made into tissue sections.
Counting the number of nerves around the tumor tissue in 
H&E stained sections
Microscopic analysis was performed on H&E stained sec-
tions. The nerves within one field (400×) of the tumor tis-
sue were defined as being near the tumor. The nerves away
from the tumor tissue more than one field (400×) were
considered far from the tumor. The average number of
nerves near and far from the tumor tissue were deter-
mined by counting the mean value in five fields (400×).
Immunohistochemical staining and quantification
Polyclonal antibodies used in this study were rabbit anti-
MMP-2 (Boster Wuhan, China, dilution 1:100), rabbit
anti-MMP-9 (Boster Wuhan, China, dilution 1:100), rab-
bit anti-CXCL12 (Boster Wuhan, China, dilution 1:150),
rabbit anti-CXCR4 (Boster Wuhan, China, dilution 1:100)
and rabbit anti-NGF (Boster Wuhan, China, dilution
1:100). Four-micrometer sections of formalin-fixed paraf-
fin-embedded tissue were mounted on poly-L-lysine-
coated slides. The slides were air-dried and the tissue was
deparaffinized. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide in 50% methanol for
10 min at room temperature. The sections were rehy-
drated and washed with PBS and then pretreated with cit-
rate buffer (0.01 M citric acid, pH 6.0) for 20 min at
100°C in a microwave oven. After nonspecific binding
sites were blocked by incubating in 2% normal goatPage 2 of 9
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37°C, the sections were incubated overnight at 4°C with
the primary antibody. The sections were then washed with
PBS and incubated with the secondary HRP-conjugated
antibody for 30 min at 37°C. Staining was performed by
incubating with fresh 3,3'-diaminobenzidine (DAB)
buffer. The sections were washed in running water and
counterstained with hematoxylin, followed by dehydra-
tion and mounting. PBS was utilized in place of the first
antibody for the negative control.
When stained for MMP-2, MMP-9, CXCL12, CXCR4 and
NGF, tumor cells with brown cytoplasm were considered
positive. We observed 10 fields per section at 400× mag-
nification, and positive cell numbers were counted in 100
random melanoma cells in every field. The mean percent-
age of positive cells was used to determine the expression
of the proteins in a section. All these counts were blindly
performed in at least 3 randomly chosen sections from
each mouse.
Clinical data and pathological material for human 
prostate cancer cases
Clinical data and pathological material were collected for
22 prostate cancer patients including ten cases of Gleason
grade IV and twelve cases of Gleason grade V and 20
patients with prostate hyperplasia who were seen in the
Tianjin Cancer Hospital between 1985 and 2005. The
median age of cancer patients was 68.40 ± 9.55 years
(range 57–85 years). The detail clinical and pathological
characteristics of 42 cases of samples were listed in a table
1. All these cancer patients were treated with surgery and
the surgical margin were negative.
Statistical analysis
Statistical software SPSS 10.0 (Chicago, Illinois) was used
to perform the analysis. Differences among groups were
assessed using the ANOVA test, and the least significant
difference (LSD) test was used to compare the differences
between every combination of two groups. Differences
between two groups were assessed using a t test. A P value
less than 0.05 was considered statistically significant.
Results
The invasiveness of human prostate cancer PC3 cells
In vitro, the invasiveness of PC3 cells treated with CXCL12
increased greatly. The average number of cells invading
through the Transwell chamber filter was 169.7(Figure
1A). The invasiveness was inhibited in the cells treated
with the CXCR4-specific inhibitor AMD3100 (Figure 1B).
The average number of cells invading through the Tran-
swell chamber filter was 77.3, lower than the 115.45 in
the untreated control group (Figure 1C). The differences
among the three groups were statistically significant (F =
32.00, P < 0.05) (table 2).
Tumor growth in inoculated animals
Tumor mass could be palpabled in the groin of the BALB/
C mice 10 days after inoculation. Treatments were admin-
istrated for 10 days starting on the 19th day after inocula-
tion. The average diameter of tumor was about 0.8 cm
when the mice were sacrificed (Figure 2A). There were no
deaths throughout the duration of the experiment until
the mice were sacrificed.
Pathological examination
The tumors appeared to be nodular, and most of them
had complete pseudo-encapsulation. The tumor cross sec-
tion was light pink or pale. Histologically, PC3 cells had
moderate eosinophilic cytoplasm, round nuclei and
prominent nucleoli. Many nerves grew around the tumor
lesion. Some tumor cells surrounded nerves and some
tumor cells invaded into the lamellar sheath (Figure 2B).
The average number of nerves near the tumor tissue in the
AMD3100-treated group was lowest, and the CXCL12-
Table 1: The clinical and pathological characteristics of 42 cases of prostate cancer and prostate hyperplasia
group clinical and pathological characteristics
Mean age (range) Prostate cancer 68.40 ± 9.55 (57–85)
prostate hyperplasia 64.18 ± 11.74 (45–81)
Histologic examination Prostate cancer adenocarcinoma
prostate hyperplasia Fibromuscuadenomaoid node, adenomaoid node, leiomyomaoid node 
and fibrohemangioid
Pathological evaluation Prostate cancer Gleason grade IV 10(45.5%) and Gleason grade V 12(54.5%)
prostate hyperplasia Moderate hyperplasia 12(60%) and severe hyperplasia 8(40%)
Volume(cm3) Prostate cancer 78.53 ± 29.75
prostate hyperplasia 45.25 ± 18.97
Local invasion and metastasis Prostate cancer Local invasion 14(63.4) and metastasis 2(9%)
prostate hyperplasia no
Level of prostate specific antigen in blood(ng/ml) Prostate cancer 68.57 ± 50.43
prostate hyperplasia 20.21 ± 3.27Page 3 of 9
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tumor tissue. The average number of nerves near the
tumor was statistically higher than the average number of
nerves far from the tumor in both the CXCL12-treated
group and the control group (F = 9.49, P < 0.05). Tumors
in the AMD3100-treated group seemed to have more
nerves near the tumor than far from the tumor (table 3).
The detection of CXCL12, CXCR4, MMP-2, MMP-9, and 
NGF expression by immunohistochemical staining
NGF was highly expressed in tumor cells as well as nerve
tissue around the tumor (Figure 2C). Among the three
groups, all of these proteins were expressed most strongly
in the tumors of the CXCL12-treated group and most
weakly in the AMD3100-treated group. CXCL12 expres-
sion was detected in tumor cells and Schwann cells
around the tumor by immunohistochemical staining, and
some weak staining was found occasionally in mesenchy-
mal cells (Figure 2D). CXCR4 was strongly expressed in
tumor cells (Figure 2E). Clear immunohistochemical
staining for MMP-2 and MMP-9 was detected in tumor
cells and some mesenchymal cells (Figures 2F &2G). The
positive cell number of CXCL12, CXCR4, MMP-2, MMP-9
and NGF expression of tumor cells in CXCL12-treated
group was the highest. The differences in the number of
positive cells for these proteins among the three groups
were statistically significant (F = 18.77 for CXCL12, 78.05
for CXCR4, 40.54 for MMP-2, 32.66 for MMP-9, 22.54 for
NGF, P < 0.05) (table 4).
The expression of CXCL12, CXCR4, MMP-2 and MMP-9 
in human prostate tissue
The cells in hyperplastic prostate tissue differentiated well
with glandular tube-like arrangement (Figure 3A). In
prostate cancer tissue, many nerves grew around the
tumor tissue. Some tumor cells surrounded nerves and
invaded into the lamellar sheath (Figure 3B). Almost all
tumor cells were positive for MMP-2 and MMP-9 staining
(Figure 3C–D). The expression of these two proteins in
prostate cancer was statistically higher than in prostate
hyperplasia (t = 3.55; t = 2.38; P < 0.05) PNI was common
in human prostate cancer. Results of immunohistochem-
ical staining showed that both nerves and tumor cells
expressed CXCL12 (Figure 3E). CXCL12 expression in
prostate cancer was significantly stronger than in prostate
hyperplasia (t = 4.55, P < 0.05). CXCR4 was expressed
mainly in tumor cells, and it was also detected, but less
intensely, in prostate hyperplasia (t = 3.86, P < 0.05) (Fig-
ure 3F) (table 5).
Discussion
Prostate cancer is the most commonly diagnosed malig-
nancy and the second leading cause of cancer-related
deaths in the Western male population[8]. Its incidence in
A: CXCL12-treated groupFigure 1
A: CXCL12-treated group. The number of invading PC3 cells was higher than that found in the other two groups. H&E, 
100×. B: Untreated control group. Some PC3 cells migrated through the ECM gel to the lower layer. H&E, 100×. C: 
AMD3100-treated group. The number of invading PC3 cells was much lower than that found in the other two groups. H&E, 
100×.
Table 2: The average number of invading cells in the three groups
Groups CXCL12-treated group (n = 4) Untreated control group (n = 4) AMD3100-treated group (n = 4)
Average number of invading cells 169.7 ± 47.23# 115.45 ± 26.49 77.30 ± 33.30
F value 32.00
# The differences of average number of invading cells between the CXCL12-treated group and the control group is statistically significant. (P < 
0.05).Page 4 of 9
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1993 to 7.9 per 100,000 men in 2005. PNI is one of the
most important characteristic of prostate cancer, as well as
the cause of frequent recurrence and poor prognosis. PNI
usually occurs in critical local nerves, and influences
patients' quality of life and causes the disease difficult to
cure[9]. Recurrence and metastasis are common when the
disease is diagnosed in the later stages and mean a poor
prognosis. Residual tumor tissue in nerve tissue is to
blame for extracapsular spread and recurrence, which
often results in treatment failure. Reports suggest that
79% of prostate cancer samples obtained during surgery
display PNI [10] and that PNI is associated with tumor
pathological grade, clinical stage and Gleason score. Elu-
cidation of the trigger and mechanism involved in pros-
tate cancer PNI is critical for improving prognosis and
promoting clinicians choose the most appropriate ther-
apy.
Besides their well-established roles in the inflammatory
reaction, chemokines participate in many physiological
and pathological behaviors including lymphocyte hom-
A: The gross appearance of tumor mass present in a BALB/C mouse 28 days after inoculation with PC3 prostate cancer cellsFigur  2
A: The gross appearance of tumor mass present in a BALB/C mouse 28 days after inoculation with PC3 pros-
tate cancer cells. B: Sporadic PC3 cells infiltrate into nerve tissue. The arrows indicate nerve tissue. H&E, 100×. C: Sporadic 
PC3 cells infiltrated the nerve. Both PC3 cells and nerve tissue express NGF. The red arrows indicated nerve tissue. NGF 
immunohistochemical staining (SP), 100×. D: Sporadic PC3 cells infiltrate the nerve. Both PC3 cells and nerve tissue expressed 
CXCL12. Red arrow indicates nerve tissue secreting CXCL12. Blue arrow indicates tumor cells. CXCL12 immunohistochemi-
cal staining (SP), 100×. E: Sporadic PC3 cells infiltrate the nerve. PC3 cells expresse CXCR4. The arrow indicate nerve tissue. 
CXCR4 immunohistochemical staining (SP), 100×. F: PC3 cells express MMP-2 that degrades ECM around nerve tissue and 
promotes PNI. The red arrow indicates nerve tissue. MMP-2 immunohistochemical staining (SP), 200×. G: PC3 cells express 
MMP-9 that degrades ECM around nerve tissue and promotes PNI. The red arrow indicates the nerve tissue. MMP-9 immuno-
histochemical staining (SP), 200×.Page 5 of 9
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esis and so on [11]. Of late, increasing evidences suggested
that chemokines were closely related to tumor growth,
invasion and metastasis[12]. Among the family of chem-
okines and their receptors that significantly contribute to
the initiation, progression, invasion and metastasis of
tumors, tumor cells expressing high CXCR4 are often
found in tissue expressing CXCL12, perhaps due to organ-
specific metastasis[13]. One possible mechanism involves
chemokines combining with their receptors to induce
membrane wrinkling in tumor cells that forms pseudopo-
dia. The tumor cells then adhere to and traverse through
the extracellular matrix and basal membrane to enter the
blood circulation and metastasize. However, there are not
reports about chemokines and their recepters involving
with PNI. Furthermore, The previous views suggested that
tumor cells express high CXCR4 and the metastasis-tar-
geted organs express high CXCL12, so the tumor cells
were attracted to the ligand in these organs[14]. In our
study, tumor cells not only expressed CXCR4, but also
CXCL12. CXCR4 and CXCL12 jointly promote prostate
cancer PNI. This phenomenon indicates that there may be
autocrine stimulation by CXCL12 in tumor tissue. Some
research validated that tumor cells can also express
CXCL12. Taichman[15] showed that PC3 and DU145
prostate cancer cell lines and hormone-resistant LnCaP
and C4-2B prostate cancer cell lines can express CXCL12.
Prostate cancer cells with significant CXCR4 expression
may escape from primary tumor foci, enter into the lym-
phatic and blood vessels and migrate toward cells express-
ing CXCL12. CXCL12 in normal tissue attracts the CXCR4
on the cancer cells, stimulating cell proliferation and
inducing angiogenesis [16-18].
The previous explanation for tumor PNI is that interstitial
tension around nerves is generally weak, making the
microenvironment surrounding the lamellar sheath suita-
ble for tumor cell growth. However, this explanation can-
not adequately detail the molecular mechanism involved
in prostate cancer PNI. Our study concludes with the idea
that chemokines and their receptors interacting with
MMPs contributed to prostate cancer PNI. CXCL12 can
induce tumor cell secretion of MMP-9 that then degrades
the blood vessel basal membrane, remodels vessels and
stimulates growth of new vessels. All of these features
together make it possible for tumor cells to easily enter the
circulation. At the same time, MMPs can similarly induce
CXCR4 expression in tumor cells.
Perissinotto[19] reported that CXCL12 can markedly
upregulate the expression and activity of MMP-9 in oste-
osarcoma. In the progression of prostate cancer PNI,
CXCL12 and CXCR4 secreted by tumor cells and nerve tis-
sue induce tumor cells to migrate toward nerves. At the
same time, tumor cells secrete MMP-2 and MMP-9 that
degrade the matrix around the tumor and the nerve tissue,
promoting PNI. Our research demonstrated that the
expression of CXCL12, CXCR4, MMP-2, and MMP-9 in
prostate cancer was much higher than in hyperplastic
prostate tissue, implying that these proteins interact with
each other and together may regulate chemotactic ability
and invasiveness of tumor cells.
Table 3: The average number of nerves near and far from the tumor tissue in the three groups
Groups CXCL12-treated group (n = 8) Untreated control group (n = 10) AMD3100-treated group (n = 10)
Number of nerves near tumor 8.73 ± 4.42*# 5.11 ± 2.39* 2.80 ± 1.19#
Number of nerves far from tumor 1.91 ± 1.10 2.22 ± 1.64 1.24 ± 0.66
F value 9.49
# The differences of the number of nerves between the CXCL12-treated group and the control group and between the AMD3100-treated group 
and the control group are statistically significant. (P < 0.05).* The differences between the number of nerves near the tumor and the number of 
nerves far from the tumor in CXCL12-treated group and untreated control group are statistically significant (P < 0.05).
Table 4: The average positive cell number of CXCL12, CXCR4, MMP-2, MMP-9, and NGF expression in the three groups (  ± s)
Treatment n CXCL12 CXCR4 MMP-2 MMP-9 NGF
AMD3100 10 11.64 ± 4.96 19.81 ± 0.91 13.94 ± 4.63 12.96 ± 3.20 24.25 ± 5.41
Untreated control 10 18.30 ± 6.53 26.09 ± 5.48 22.47 ± 3.30 18.72 ± 3.26 31.72 ± 3.38
CXCL12 8 34.63 ± 5.04 53.83 ± 5.75 41.03 ± 8.21 32.97 ± 6.97 51.24 ± 13.87
F value 18.77 78.05 40.54 32.66 22.54
The differences of positive cell number of CXCL12, CXCR4, MMP-2, MMP-9 and NGF expression of tumor cells among the three groups were all 
statistically significant(P < 0.05).
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etrate ECM gel. Initially in this process, chemokines com-
bining with their receptors cause actin to concentrate and
enhance cell mobility. Muller [20] reported that CXCL12
could increase the concentration of F-actin in breast can-
cer cells in vivo, thus facilitate the breast cancer cells'
migration and invasion in a specific direction. Secondly,
CXCR4 combining with CXC12 can rapidly stimulate
transmembrane transporting of Ca2+. Vaday[21] showed
the specific antibody against human CXCR4 scFv could
significantly inhibit the Ca2+ transport mediated by
CXCL12 and CXCR4. Thirdly, CXCL12 promotes tumor
cell adhesion to the basement membrane components.
AMD3100 is a small highly specific non-peptide antago-
nist of CXCR4[6]. It can inhibit the signal transduction of
CXCL12 mainly through a route that does not involve the
ligand-receptor interaction. AMD3100 is capable of inhib-
iting infiltration by acute lymphoblastic leukemia and
ovarian cancer cells[7]. AMD3100 competitively inhibited
the CXCR4 binding with CXCL12 and blocked the down-
stream pathway. In addition, AMD3100 can promote
A: The cells in hyperplastic prostate tissue differentiated well with glandular tube-like arrangementFigur  3
A: The cells in hyperplastic prostate tissue differentiated well with glandular tube-like arrangement. H&E, 100×. 
B: Human prostate cancer tumor cells grow around the nerve. Some tumor cells have invaded into nerve tissue. The red arrow 
indicates the nerve, H&E, 100×. C: Cells in a human prostate cancer tumor around the nerve express MMP-2 that degrades the 
ECM around the nerve tissue and promotes PNI. The red arrow indicates nerve tissue. MMP-2 immunohistochemical staining 
(SP), 100×. D: Cells in human prostate cancer tumor around the nerve express MMP-9 that degrades the ECM around the 
nerve tissue and promotes PNI. The red arrow indicates nerve tissue. MMP-9 immunohistochemical staining (SP), 100×. E: 
Prostate cancer cells infiltrate the nerve. Both tumor cells and nerve tissue express CXCL12. Red arrow indicates nerve. Blue 
arrow indicates tumor cells. CXCL12 immunohistochemical staining (SP), 100×. F: Prostate cancer cells expressing CXCR4 
infiltrate the nerve. The red arrow indicates nerve tissue. CXCR4 immunohistochemical staining (SP), 100×.
Table 5: The average positive cell number of CXCL12, CXCR4, MMP-2, and MMP-9 expression in prostate cancer and prostate 
hyperplasia (  ± s)
groups n CXCL12 CXCR4 MMP-2 MMP-9
Prostate cancer 22 37.30 ± 13.24* 37.09 ± 14.66* 42.86 ± 15.44* 52.48 ± 23.51*
Prostate hyperplasia 20 2.87 ± 1.17 3.27 ± 0.71 11.23 ± 5.10 19.22 ± 4.75
t value 4.55 3.86 3.55 2.38
*The difference between prostate cancer and prostate hyperplasia is statistically significant (P < 0.05).
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transduction pathway about the CXCL12 and CXCR4
interaction.
Nerve growth factor (NGF) not only promotes nerve tis-
sue growth, development and regeneration, but regulates
the growth and metastasis of pancreatic cancer, prostate
cancer, lung cancer and retinal glioblastoma cells[22].
Results of Oelmann et al[23]. indicated NGF promotes
proliferation in three kinds of lung cancer cell lines, and
the effect took on dose-dependent. This effect could be
blocked by NGF antibody. Research from Zhu et al. [24]
showed that pancreatic cancer cells expressed NGF and
lamellar sheath expressed TrkA, a combination of receptor
and ligand that attracts tumor cells to nerves, leading to
invasion and metastasis along nerves. In addition, NGF
stimulated the expression of MMPs in tumor cells. Our
results indicated that the expression of NGF in the
CXCL12-treated group was much higher than that in the
control group and the AMD3100-treated group. Of the
three groups, the CXCL12-treated group had the highest
average number of nerves around tumor. This study sug-
gested that CXCL12 could increase NGF expression in PC3
cells. NGF could combine with its receptor expressed on
the cell surface to activate the corresponding signal trans-
duction pathway, enhancing the cells' invasiveness and
mobility toward nerves. NGF secreted by tumor cells
could also enhance the synthesis and release of some fac-
tors including MMPs that promoted cell invasion and
metastasis. Furthermore, NGF diffuses around tumor tis-
sue and stimulates nerve growth along this concentration
gradient, enabling tumor cells to invade nerves and metas-
tasize. Meanwhile, the increased number of nerves in
tumor mass can secrete numerous factors to promote
tumor cell growth.
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